Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 2.1.1.127 - [ribulose-bisphosphate carboxylase]-lysine N-methyltransferase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Carcinogenesis
Protein lysine methyltransferase SMYD3 is involved in tumorigenesis through regulation of HER2 homodimerization.
Carcinoma
Overexpression of SET and MYND Domain-Containing Protein 2 (SMYD2) Is Associated with Tumor Progression and Poor Prognosis in Patients with Papillary Thyroid Carcinoma.
WHSC1L1 drives cell cycle progression through transcriptional regulation of CDC6 and CDK2 in squamous cell carcinoma of the head and neck.
Carcinoma, Squamous Cell
WHSC1L1 drives cell cycle progression through transcriptional regulation of CDC6 and CDK2 in squamous cell carcinoma of the head and neck.
Infections
The methyltransferase Setdb2 mediates virus-induced susceptibility to bacterial superinfection.
Influenza, Human
The methyltransferase Setdb2 mediates virus-induced susceptibility to bacterial superinfection.
Intellectual Disability
Identification of protoberberine alkaloids as novel histone methyltransferase G9a inhibitors by structure-based virtual screening.
Leukemia
Bromo-deaza-SAH: A potent and selective DOT1L inhibitor.
SETDB2 Links E2A-PBX1 to Cell-Cycle Dysregulation in Acute Leukemia through CDKN2C Repression.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeting protein lysine methyltransferase G9A impairs self-renewal of chronic myelogenous leukemia stem cells via upregulation of SOX6.
Leukemia, Myeloid
Bromo-deaza-SAH: A potent and selective DOT1L inhibitor.
Neoplasm Metastasis
Downregulation of NSD3 (WHSC1L1) inhibits cell proliferation and migration via ERK1/2 deactivation and decreasing CAPG expression in colorectal cancer cells.
Kinetic isotope effects reveal early transition state of protein lysine methyltransferase SET8.
Neoplasms
Analysis of the Substrate Specificity of the SMYD2 Protein Lysine Methyltransferase and Discovery of Novel Non-Histone Substrates.
Downregulation of NSD3 (WHSC1L1) inhibits cell proliferation and migration via ERK1/2 deactivation and decreasing CAPG expression in colorectal cancer cells.
Identification of protoberberine alkaloids as novel histone methyltransferase G9a inhibitors by structure-based virtual screening.
Inhibition of SMYD2 Sensitized Cisplatin to Resistant Cells in NSCLC Through Activating p53 Pathway.
Kinetic isotope effects reveal early transition state of protein lysine methyltransferase SET8.
Optimization of Cellular Activity of G9a Inhibitors 7-Aminoalkoxy-quinazolines.
Overexpression of SET and MYND Domain-Containing Protein 2 (SMYD2) Is Associated with Tumor Progression and Poor Prognosis in Patients with Papillary Thyroid Carcinoma.
Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines.
SMYD2 suppresses p53 activity to promote glucose metabolism in cervical cancer.
Somatic Cancer Mutations in the SUV420H1 Protein Lysine Methyltransferase Modulate Its Catalytic Activity.
Structural basis for the methylation site specificity of SET7/9.
The Discovery of Novel Histone Lysine Methyltransferase G9a Inhibitors (Part 1): Molecular Design Based on a Series of Substituted 2,4-Diamino-7-aminoalkoxyquinazoline by Molecular-Docking-Guided 3D Quantitative Structure-Activity Relationship Studies.